Rheumatoid arthritis is a heterogeneous disease, which can be, based on data combining
genetic risk factors and autoantibodies, sub-classified into ACPA-positive and-negative RA …

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation,
which affects approximately 1% of the population. The benefit of early recognition and …

Background Rheumatoid arthritis is the most common autoimmune disease worldwide and
requires long-term treatment to suppress inflammation. Currently, treatment is started when …

Rheumatoid arthritis (RA) is currently diagnosed and treated when an individual presents
with signs and symptoms of inflammatory arthritis (IA) as well as other features, such as …

Individuals at high risk of developing seropositive rheumatoid arthritis (RA) can be identified
for translational research and disease prevention studies through the presence of highly …

Musculoskeletal diseases affect up to 20% of adults worldwide. The gut microbiome has
been implicated in inflammatory conditions, but large-scale metagenomic evaluations have …

Rheumatoid arthritis (RA) is a chronic autoimmune disease considered as a multistep
process spanning from the interaction of genetic (eg, shared epitope or non-HLA loci) …

Background Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical
inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment …

The concept of a 'window of opportunity'in treating a disease assumes the existence of a
time frame during which the trajectory of the disease can be effectively and permanently …

Background Individuals with serum antibodies to citrullinated protein antigens (ACPA),
rheumatoid factor, and symptoms, such as inflammatory joint pain, are at high risk of …